The presentation will provide an update on three ongoing PDS0101 phase 2 clinical trials. In the Versatile-002 phase 2 clinical trial, PDS Biotech is collaborating with MERCK & Co., to evaluate a combination of PDS0101 and KEYTRUDA® (NCT04260126). Versatile-002 is studying the combination in first-line treatment of recurrent or metastatic head and neck cancer, and in second-line treatment of recurrent or metastatic head and neck cancer in patients who have failed prior checkpoint inhibitor therapy. In addition, the Company is conducting a phase 2 clinical study in both second- and third-line treatment of multiple advanced HPV-associated cancers. This study is being led by the
The presentation will also provide updates on the progression of two other investigational pipeline immune-oncology products. PDS0102 (Versamune® + TARP) addresses prostate cancer, breast cancer and AML, and PDS0103 (Versamune® + MUC1) addresses multiple cancers including breast, colon, lung, and ovarian cancers.
The conference is taking place virtually on
B.
Date:
Time:
Investors can register for the conference HERE.
Following the conference, a webcast replay of the presentation will be available on the Investor section of the company’s website,
About
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.
Our Infectimune™ -based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Investor Contact:
Phone: +1 (404) 736-3838
pdsb@cg.capital
![](https://ml.globenewswire.com/media/YzcwMmY1YzUtZTYxYS00ZThmLTlmYzAtMjdjMGI0NDg3OTI1LTEwMjg3NjE=/tiny/PDS-Biotechnology-Corporation.png)
2022 GlobeNewswire, Inc., source